Physician profile
Michael E Raizner
NPI 1417931155
$1,770.72
in general payments reported to CMS, 2019-2025
18 companies · $92.07 in 2025
The $92.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $98.70 · 2021: $150 · 2022: $426 · 2023: $257 · 2024: $467 · 2025: $92.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $298.35 | 2020-2023 | Xarelto |
| Boston Scientific Corporation | $257.47 | 2022-2024 | Watchman Flx, Bodyguardian |
| Abbott Laboratories | $202.07 | 2019-2024 | Jot Dx, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.32 | 2021-2024 | Lifevest |
| Medtronic, INC. | $137.00 | 2024-2025 | Linq II, Hawkone |
| E.R. Squibb & Sons, L.L.C. | $128.12 | 2019-2024 | Eliquis |
| Medtronic Vascular, INC. | $121.53 | 2019 | |
| Heartflow, INC. | $107.82 | 2019-2023 | Ffrct |
| Novartis Pharmaceuticals Corporation | $93.29 | 2022-2024 | |
| Amgen INC. | $76.90 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.27 | 2022-2023 | Jardiance |
| Preventice Services, LLC | $25.86 | 2019 | |
| Tactile Systems Technology INC | $22.12 | 2024 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $20.72 | 2021 | |
| Agepha Pharma Fz LLC | $20.26 | 2024 | Lodoco |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.71 | 2021 | |
| Amarin Pharma, INC. | $15.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raizner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.